Origgi is joining Valo Therapeutics as CEO after four years at investment unit Johnson and Johnson Innovation,
Marcella Origgi, new ventures lead at US pharmaceutical and biotech company Johnson & Johnson, has left the corporate to become chief executive of immunotherapy startup Valo Therapeutics.
Origgi will assume the helm of Valo Therapeutics’ Helsinki headquarters and its Naples subsidiary after a four-year stint leading new ventures and early innovation partnering at Johnson & Johnson Innovation, the corporate’s corporate venturing arm.
She joined the company shortly following its recent €19m ($22m) funding round backed by Indaco Venture Partners, CDP Venture Capital and Fondazione ENEA Tech e Biomedical. The startup is working on the development of antigen-coated viruses to use against cancer cells in the body.
“I am looking forward to working with the talented team in Helsinki and Naples to drive clinical development across our expanded global footprint to advance life-changing treatments for patients worldwide,” said Origgi.
Prior to Johnson & Johnson, she worked at The Janssen Pharmaceutical Company as engagement manager for scientific associations and patient advocacy.
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
